1. Pink Sheet
  2. >>Geography
  3. >>Europe

EU-Wide Restrictions In Store For Bayer's Prostate Cancer Drug

 
• By Vibha Sharma

Several medicines referred to the European Medicines Agency on issues relating to safety or benefit-risk profile are being discussed by the agency's medicines evaluation committee, the CHMP, this week.

Held back metaphor as a large anchor holding or oppressing an air balloon and restricting movement as a suppression business metaphor from aspiring to succeed with 3D illustration elements.
PRAC Had Recommended Restricting Xofigo's Use After Reviewing Safety Data • Source: Shutterstock

The European Medicines Agency's drug evaluation committee, the CHMP, is set to adopt final recommendations on restricting the EU-wide use of Bayer's prostate cancer medicine Xofigo. The CHMP is also expected to discuss several other medicines referred to the EMA for resolution of issues relating to their safety or benefit-risk balance.

The recommendations in relation to Xofigo (radium-223 dichloride) were issued earlier this month by the EMA's pharmacovigilance committee, the PRAC,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

Swissmedic Appoints Trivigno As New Agency Head From 2026

 
• By Anabel Costa-Ferreira

Vincenza Trivigno will take over as executive director from Raimund Bruhin, who is retiring after over seven years in the post.

New EFPIA President Hopes ‘Sanity Will Prevail’ In EU Pharma Reform Dialogs

 
• By Eliza Slawther

Stefan Oelrich, the newly-announced president of European pharma industry federation EFPIA says the EU pharma reform is “not an improvement on the status quo” in its current form.

Denmark Introduces First Confidential Pricing Framework For Primary Care Medicines

 
• By Francesca Bruce

Expanded confidential pricing for pharmaceuticals is intended to help manage medicines expenditure, according to Amgros, the procurement agency that will negotiate the prices.

Repurposed Drugs: EU Pharma Reform Offers Boost, But Payers ‘Must Recognize Health Gains’

 
• By Eliza Slawther

Incentives for repurposed drugs proposed as part of the EU pharma reform package are a “great step forward,” but more recognition is needed from payers and regulators to leverage the benefits of these medicines, experts say.

More from Geography

New EFPIA President Hopes ‘Sanity Will Prevail’ In EU Pharma Reform Dialogs

 
• By Eliza Slawther

Stefan Oelrich, the newly-announced president of European pharma industry federation EFPIA says the EU pharma reform is “not an improvement on the status quo” in its current form.

UK Pilots Faster Setup Of Early Phase Oncology Trials

 
• By Vibha Sharma

Oncology trial sponsors in the UK are being invited to participate in a pilot that aims to tackle duplication and variation in pharmacy reviews, which are an important part of setting up clinical trials in the National Health Service.

US CDC Vaccine Committee Revives Thimerosal Debate: A Portent Of Things To Come?

 
• By Bridget Silverman

The new Advisory Committee on Immunization Practices voted for new recommendations on the decades-old thimerosal safety issue and lays intellectual groundwork to revisit other past controversies and decisions.